Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominik Wolf

Showing results (301-310 of 331) with videos related to

Pageof 34
Sort By:
Blood|May 22, 2020
A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic diseaseVerena Petzer, Piotr Tymoszuk, Malte Asshoff, et al.
NPJ Precision Oncology|July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemKai Zimmer, Florian Kocher, Gerold Untergasser, et al.
Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
The Lancet. Respiratory Medicine|June 14, 2021
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Michael Schreinlechner, Nikolay Sappler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Pageof 34

Showing results (301-310 of 331) with videos related to

Sort By:
Pageof 34
Blood|May 22, 2020
A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic diseaseVerena Petzer, Piotr Tymoszuk, Malte Asshoff, et al.
NPJ Precision Oncology|July 3, 2023
PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair systemKai Zimmer, Florian Kocher, Gerold Untergasser, et al.
Blood|September 13, 2019
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasmsTata Nageswara Rao, Nils Hansen, Julian Hilfiker, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Blood|December 8, 2025
Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trialAnne Sophie Platzbecker, Julia Annabell Georgi, Jan Moritz Middeke, et al.
Blood|December 20, 2018
Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with <i>FLT3</i>-ITDRichard F Schlenk, Daniela Weber, Walter Fiedler, et al.
Blood Advances|December 11, 2024
Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World StudyEvgenii Shumilov, Rebecca Wurm-Kuczera, Andrea Kerkhoff, et al.
The Lancet. Respiratory Medicine|June 14, 2021
Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trialAxel Bauer, Michael Schreinlechner, Nikolay Sappler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With <i>FLT3</i>-Internal Tandem Duplication Mutation (SORMAIN)Andreas Burchert, Gesine Bug, Lea V Fritz, et al.
Hemasphere|October 31, 2022
Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA ReportJon Salmanton-García, Francesco Marchesi, Andreas Glenthøj, et al.
Pageof 34